Metabolic Syndrome: A Cluster of Cardiometabolic Risk
Metabolic syndrome—defined by central obesity, elevated triglycerides, low HDL, hypertension, and impaired fasting glucose—affects approximately one-third of US adults and dramatically increases cardiovascular disease and type 2 diabetes risk. PFAS affect each individual component of metabolic syndrome through distinct but overlapping mechanisms.
PFAS and All Five Metabolic Syndrome Components
PFAS promote central adiposity through PPAR-gamma activation; elevate triglycerides by impairing hepatic lipid clearance; lower HDL by altering hepatic ApoA-I synthesis; increase blood pressure through endothelial dysfunction; and impair fasting glucose through beta cell toxicity and insulin receptor signaling disruption. This multicomponent metabolic disruption means PFAS-exposed individuals face simultaneously worsened risk for every metabolic syndrome criterion.
Dose-Response Evidence
Cross-sectional analyses show dose-response associations between PFAS serum levels and metabolic syndrome prevalence in population studies. The effect sizes for individual PFAS compounds are modest—but multiple co-occurring PFAS compounds acting through the same pathways produce combined effects substantially greater than any single compound would predict.
Cardiometabolic Prevention Implications
Cardiologists and endocrinologists managing metabolic syndrome should incorporate environmental PFAS exposure assessment in their evaluation of patients with unexplained or unusually severe metabolic dysfunction. PFAS exposure reduction combined with standard lifestyle modifications may provide additive benefit for metabolic syndrome management in chemically exposed patients